Preview Mode Links will not work in preview mode

Evidence Based Medicine presented by InpharmD™


Jan 20, 2022

A double-blind, randomized, placebo-controlled trial conducted to evaluate the efficacy and safety of a 3-day course of remdesivir in high-risk, non-hospitalized patients with COVID-19.